Thrivent Financial for Lutherans
CNCE

Thrivent Financial for Lutherans’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Thrivent Financial for Lutherans’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-70,597
Closed -$415K – 2275
2019
Q3 		$415K Sell
70,597
-34,959
-33% -$371K ﹤0.01% 1929
2019
Q2 		$1.27M Buy
105,556
+1,361
+1% +$14.6K ﹤0.01% 1252
2019
Q1 		$1.26M Buy
104,195
+2,314
+2% +$34.1K ﹤0.01% 1210
2018
Q4 		$1.28M Buy
101,881
+377
+0.4% +$5.21K ﹤0.01% 1029
2018
Q3 		$1.51M Sell
101,504
-12,237
-11% -$193K ﹤0.01% 1032
2018
Q2 		$1.91M Buy
113,741
+614
+0.5% +$11.9K 0.01% 930
2018
Q1 		$2.59M Buy
+113,127
New +$2.52M 0.01% 808

Other funds holding CNCE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Thrivent Financial for Lutherans's CNCE Position: Q4 2019 in Review

Thrivent Financial for Lutherans sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q4 2019, closing a stake of 70,597 shares — an estimated $415K sold.

Thrivent Financial for Lutherans first reported a position in CNCE in Q1 2018 and held it in 7 quarters. The position peaked at $2.59M in Q1 2018. 77 funds tracked by Wall St. Rank hold CNCE as of Q4 2019.

  • Thrivent Financial for Lutherans reported no remaining Concert Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
  • Thrivent Financial for Lutherans sold 70,597 Concert Pharmaceuticals, Inc. shares in Q4 2019, an estimated $415K.
  • Thrivent Financial for Lutherans first reported a position in Concert Pharmaceuticals, Inc. in Q1 2018 and held it in 7 quarters.
  • Thrivent Financial for Lutherans's Concert Pharmaceuticals, Inc. position peaked at $2.59M in Q1 2018.
  • 77 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q4 2019.

Based on Thrivent Financial for Lutherans's 13F filing for Q4 2019, filed 13 Feb 2020.